Call Buying Activity in AbbVie (ABBV) Targets 3% Upside in Shares Into Mid-November Ahead Various Drug Trials -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
AbbVie (ABBV): Cutting PT Slightly After Earnings - Leerink
October 30, 2017 7:59 AM EDTLeerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Abbvie (NYSE: ABBV) and cut his price target to $107 from $108.after the company reported Q3 financial results that were inline with expectations. Total product revenue was in-line with consensus and EPS slightly above... More
AbbVie (ABBV) Tops Q3 EPS by 3c, Lifts FY EPS Guidance
October 27, 2017 7:42 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $1.41, $0.03 better than the analyst estimate of $1.38. Revenue for the quarter came in at $7 billion versus the consensus estimate of $7 billion.
GUIDANCE:
AbbVie sees FY2017 EPS of $5.53-$5.55, versus the consensus of $5.53.
Update To... More
AbbVie (ABBV) Raises Quarterly Dividend 10.9% to $0.71; 3.2% Yield
October 27, 2017 7:32 AM EDTAbbVie (NYSE: ABBV) declared a quarterly dividend of $0.71 per share, or $2.84 annualized. This is a 10.9% increase from the prior dividend of $0.64.
The dividend will be payable on February 15, 2018, to stockholders of record on January 12, 2018, with an ex-dividend date of January 11,... More
AbbVie (ABBV) Announces FDA Priority Review for Elagolix for Management of Endometriosis with Associated Pain
October 27, 2017 7:01 AM EDTAbbVie (NYSE: ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered... More
AbbVie (ABBV) Says Risankizumab Met All Co-Primary and Ranked Secondary Endpoints in Three Pivotal Phase 3 Psoriasis Studies
October 26, 2017 8:47 AM EDTAbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal Phase 3 clinical trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, compared to ustekinumab and adalimumab for the treatment of patients with moderate to severe chronic plaque psoriasis.1,2,3 Results showed that after 16 weeks of treatment, risankizumab (150 mg) met the co-primary endpoints of at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) and a static Physician Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) across all three studies versus placebo or adalimumab... More
